“They’re Regrowing Cartilage in Japan.” What Your Surgeon Actually Wants You to Know
iPS-cell cartilage in Japan and AMIC in Germany are real — but not yet available here. What's actually happening abroad, why the US is slower, and what I can offer you today.
I hear some version of this at least once a week in my office: "I read that in Japan they're regrowing cartilage with stem cells," or "my friend went to Germany and got a procedure that isn't available here." Patients come in hopeful — sometimes frustrated that the US seems to be lagging behind. I want to give you an honest answer, because this is a conversation worth having.
The short version: yes, some of it is real. And yes, some of it is genuinely ahead of what I can offer you today. But the distance between a compelling research result and a treatment you can actually get in my office is almost always longer than the headline suggests.
What's actually happening in Japan and Germany
Japan — iPS cell cartilage
Osaka University has made genuine breakthroughs using induced pluripotent stem cells (iPS cells) to grow cartilage organoids that can be transplanted into damaged joints. In a primate study published in Nature Communications, these lab-grown cartilage implants survived, integrated with surrounding tissue, and prevented osteoarthritis from developing. A Phase III clinical trial for a related stem cell therapy has already started in Japan.
This is real, it's not science fiction — and Japan's regulatory agency has a "conditional early approval" pathway that allows treatments to reach patients faster than the FDA typically allows. That's a legitimate regulatory difference, not just American slowness.
Germany — AMIC
A procedure called AMIC (Autologous Matrix-Induced Chondrogenesis) has been widely performed in Europe, including Germany, for cartilage defects. It combines standard microfracture with a collagen membrane called ChondroGide that protects the healing cells and improves the quality of repair tissue. A 10-year randomized controlled trial published in 2024 showed AMIC produced significantly better outcomes than microfracture alone.
The catch: the ChondroGide membrane that makes AMIC work is not FDA-approved for this indication in the United States. Patients who have gone to Germany for this had a real procedure — it's just not cleared for use here yet.
The pipeline problem — and what it means for you
Here's the framework I use when patients bring me these stories. Almost every exciting orthopedic treatment goes through the same long pipeline before it becomes something I can offer you:
| Stage | Timeline | Where Japan and Germany often are |
|---|---|---|
| Lab / animal research | Years 1–5 | Public headlines originate here |
| Phase I/II human trials | Years 5–10 | Japan's iPS cartilage; Germany's AMIC at earlier stages |
| Phase III + regulatory approval | Years 10–15 | FDA (US) vs. PMDA (Japan) vs. EMA (Europe) |
| Standard clinical use | Year 15+ | What I can offer you in my office today |
The FDA's rigorous approval process is genuinely slower than Japan's or Europe's — and that's partially by design. The US requires larger, longer Phase III trials demonstrating both safety and efficacy before approving new treatments. Japan's conditional approval system can get therapies to patients faster but with the expectation that more data will be collected post-approval. Both systems have real tradeoffs.
What this means practically: when you read about iPS cell cartilage transplants in Japan, you're reading about a Phase I/II clinical trial in a handful of patients. It is promising. It is not something I can perform next Tuesday. The typical path from discovery to FDA approval runs 10 to 15 years — and roughly 90% of promising therapies don't make it all the way through.
The research is further along than most patients realize. The clinical translation is further away than most headlines suggest.
What I can actually offer you today
Here's what often gets lost in these conversations: the US does have excellent cartilage restoration options available right now. MACI — matrix-associated autologous chondrocyte implantation — is FDA-approved and is one of the most sophisticated cartilage repair procedures available anywhere in the world. We take your own cartilage cells, culture them in a lab, and implant them on a scaffold that supports regrowth in a focal defect. About 85% of implants survive and function long-term. That's not a consolation prize — that is genuinely advanced medicine.
For patients with broader arthritis rather than focal defects, PRP injections now have strong Level 1 evidence for meaningful pain and functional improvement, especially when prepared with high platelet concentration. And when the joint damage is too advanced, a partial or total knee replacement — done well, with the right implant for your anatomy — can give you a decade or more of pain-free function.
I stay closely connected to the research pipeline, including international trials. When something crosses the threshold from "promising" to "proven and available," I'll be among the first to offer it. Until then, my job is to give you the most honest picture I can — not to sell you on a future we don't have yet, and not to dismiss it either.
Frequently asked questions
Should I travel to Japan or Germany for a cartilage procedure?
For most patients, no — and I'd be cautious about anyone aggressively promoting that path. "Clinical trial" means we're still learning whether it works and is safe. The patients best suited for experimental procedures internationally are typically those who have exhausted available options here, and that decision should be made carefully with a surgeon who knows your full picture.
Is the US really behind other countries in orthopedic care?
In regulatory speed for some cutting-edge therapies, yes — Japan and parts of Europe move faster. In overall orthopedic outcomes, surgical volume, and implant technology, the US is among the world leaders. I was trained at the Hospital for Special Surgery in New York, ranked #1 in orthopedics nationally, and I'd put the care available there and at practices like mine against anywhere in the world.
What cartilage options are available to me right now?
Depending on your age, the extent of damage, and your activity goals: MACI or osteochondral allograft for focal cartilage defects, PRP for early arthritis, and partial or total knee replacement for more advanced joint disease. Come in and we can look at your imaging and figure out exactly where you are in the picture.
The science is moving fast — faster than at any point in the history of this specialty. I'm genuinely excited about what's coming. But the best decision you can make today is to get a clear picture of where your joint actually is and what's available to treat it right now. That's what I'm here for.
This article is general education, not medical advice for your situation. Every knee and hip is different — talk with your own doctor about your care.